How Exactly Does Wegovy Work — and What Does That Mean for You?

The hormone Wegovy is built to copy

GLP-1 stands for glucagon-like peptide-1. Your gut releases it naturally when food arrives, and it does several things at once: it tells your pancreas to release insulin, it signals your brain that you have eaten, and it slows the passage of food through your digestive system. The problem is that natural GLP-1 breaks down within minutes. Semaglutide is an engineered version of the same molecule, modified so it binds to albumin in the blood and survives long enough for a once-weekly injection to keep it active throughout the week.

That durability is the core innovation. You are not adding a foreign signal to your body; you are amplifying one it already uses, just for far longer than it normally would. The NHS medicines page on semaglutide describes this mechanism clearly for anyone who wants the patient-level summary. If you are curious how this compares to the experience of people already using it, the wider picture of what Wegovy does in practice goes into the day-to-day effects.

One thing worth knowing early: the medicine does not bypass hunger permanently. It recalibrates the signal. Most people find the effect builds gradually across the titration schedule, which starts at 0.25 mg and rises in roughly four-weekly steps toward 2.4 mg. That slow climb exists to give your digestive system time to adjust.

Where the signal goes, brain, gut and blood sugar

The GLP-1 receptor sits in several places at once. In the gut, activation slows gastric emptying: meals feel heavier and stay with you longer, so the urge to eat again comes later. In the pancreas, semaglutide prompts insulin release in proportion to blood sugar, so the effect is glucose-dependent and does not cause the hypoglycaemia associated with older diabetes drugs. In the brain, the hypothalamus and the brainstem both carry GLP-1 receptors, and their activation appears to reduce what researchers describe as food reward: the pull toward high-calorie foods becomes less insistent.

This last point matters for the decision about whether Wegovy is right for you. If you have ever been told that struggling with weight is a willpower problem, the neuroscience here says otherwise. Weight is shaped by biology. Semaglutide does not eliminate appetite; it turns down the volume on a signal that, for many people, has always been louder than average. The full-body effects of semaglutide cover what happens beyond appetite, including cardiovascular data and the emerging picture on other organ systems.

For a deeper look at the pharmacology behind the GLP-1 class, how semaglutide works examines the mechanism from a slightly different angle, useful if you are weighing it against other options.

What the trial evidence actually shows

The STEP 1 trial ran for 68 weeks, enrolled adults with obesity or overweight plus at least one weight-related condition, and compared semaglutide 2.4 mg against placebo alongside lifestyle support. Average weight reduction in the semaglutide group was around 15% of body weight. That figure comes from the STEP 1 paper in the New England Journal of Medicine, and it is the one NICE used when recommending semaglutide for weight management under TA875.

A few things that figure does not tell you: it is an average across a range of responses; it reflects outcomes at the 2.4 mg maintenance dose, which not everyone reaches at the same pace; and it was achieved alongside a reduced-calorie diet and increased activity. Wegovy amplifies the effect of those changes, it does not replace them. Results are also not maintained if treatment stops and lifestyle changes are not sustained.

It is also worth noting that the higher 7.2 mg semaglutide dose, approved by the MHRA in early 2026, reported around 20.7% average weight loss over 72 weeks in trials, narrowing the gap with tirzepatide. If you want to explore the comparison, the difference between Ozempic and Wegovy is a good place to start, since confusion between the two is common.

The practical decision: is this mechanism relevant to your situation?

Understanding the mechanism helps you set realistic expectations rather than arrive at treatment hoping for a shortcut. Wegovy is not suitable for everyone. It is licensed for adults with a BMI of 30 or above, or 27 or above with at least one weight-related condition such as high blood pressure, type 2 diabetes or obstructive sleep apnoea. Lower BMI thresholds apply for some ethnic backgrounds under UK guidance. A prescriber reviews your full picture (not just your BMI) before any prescription is written.

It is a prescription-only medicine, and the legal route is always a clinical assessment first. The most common side effects are gastrointestinal: nausea, loose stools, constipation and indigestion, typically most noticeable after starting or after a dose increase, and often settling within days to two weeks. Serious effects are less common but include pancreatitis, severe, persistent stomach pain reaching the back warrants urgent medical attention. A full overview of the treatment landscape, including how to access Wegovy through a regulated route, is on our treatment page.

One practical note: if you are planning a holiday or you know a busy period is coming up, the titration schedule means the first month is all about tolerability, and it is also worth reading about how Wegovy can affect your skin's sensitivity to sunburn before travelling somewhere sunny. Starting treatment just before a two-week trip, or right before Christmas, is worth discussing with a prescriber first. Timing the start well is a small thing that makes the adjustment phase easier.

If you have questions about the route to treatment, our Wegovy overview covers eligibility, access and what to expect from a private consultation. When you are ready, start your free consultation and a GPhC-registered prescriber will review your details the same day.